Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
NCT00338884
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Renal Cell
Interventions
DRUG:
Sunitinib malate
Sponsor
Pfizer